A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic functio
Phase 1
Recruiting
- Conditions
- Allergic rhinitis, UrticariaMedDRA version: 20.0Level: PTClassification code: 10046735Term: Urticaria Class: 100000004858MedDRA version: 21.1Level: LLTClassification code: 10001723Term: Allergic rhinitis Class: 10038738Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Registration Number
- CTIS2022-500774-34-00
- Lead Sponsor
- Biohorm S.L.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method